Alveolar Soft Part Sarcoma is a Candidate for Therapy by Drugs that Specifically Inhibit the MET Receptor Tyrosine Kinase
A collaboration between scientists from The Memorial Sloan-Kettering Cancer Center in New York, Dana-Farber Cancer Institute in Boston and The Johns Hopkins Hospital in Baltimore reveals a new therapeutic target in Alveolar Soft Part Sarcoma. The results of that collaboration were recently published in the scientific Journal Cancer Research volume 67 pages 919-929, 2007. The […]
Two Sorafenib (Nexavar) Clinical Trials are Currently Recruiting Sarcoma Patients in Different Locations Across the USA
1. Phase II Study of Sorafenib in Patients With Advanced Soft Tissue Sarcomas 2. Sorafenib in Treating Patients With Soft Tissue Sarcomas Alveolar Soft Part Sarcoma (ASPS) is highly angiogenic: it involves intensive growth of new blood vessels into the tumor. Those blood vessels connect the tumor to the blood system, supply oxygen and nutrients […]
Update on the Clinical Trial for Alveolar Soft Part Sarcoma at the Dana Farber Cancer Institute in Boston
October 11, 2006 The clinical trial “GVAX Cancer Vaccine” started in January 2006 and enrollment is still open to new patients. So far 11 patients were selected to participate in the trial. Eight of those patients have the diagnosis of Alveolar Soft Part Sarcoma (ASPS). All the eight ASPS patients have completed the study. There […]